Is immunotherapy re-entering the kidney cancer arena from the back door? Considerations from the Phase I/II study of siltuximab

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Evaluation of: Rossi JF, Negrier S, James ND et al.: A Phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br. J. Cancer 103, 1154-1162 (2010). For years, immunotherapy was the mainstay of treatment for advanced kidney cancer. The recent development of molecularly targeted agents, and of antiangiogenic agents in particular, has completely changed this scenario, leaving immunotherapy with a minor role in treatment, if any. Recent insights in the mechanisms of resistance to these drugs suggest that the immune system could play a relevant role. In particular, IL-6 appears to cooperate with other growth factors in the recruitment of bone marrow-derived immune cells, ultimately leading to resistance to antiangiogenic agents. Furthermore, it is now clear that monoclonal antibodies actively interact with the immune system and show significant immune-modulating effects per se. Further translation research on this issue is much needed.

Original languageEnglish
Pages (from-to)487-490
Number of pages4
JournalImmunotherapy
Volume3
Issue number4
DOIs
Publication statusPublished - Apr 2011

Fingerprint

Angiogenesis Inhibitors
Kidney Neoplasms
Immunotherapy
Immune System
Interleukin-6
Monoclonal Antibodies
Renal Cell Carcinoma
Drug Resistance
Intercellular Signaling Peptides and Proteins
Bone Marrow
Therapeutics
Research
Neoplasms
siltuximab

Keywords

  • IL-6
  • immunotherapy
  • kidney cancer
  • monocolonal antibodies
  • siltuximab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

@article{1652dffb797d43fab57005e66b35d778,
title = "Is immunotherapy re-entering the kidney cancer arena from the back door? Considerations from the Phase I/II study of siltuximab",
abstract = "Evaluation of: Rossi JF, Negrier S, James ND et al.: A Phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br. J. Cancer 103, 1154-1162 (2010). For years, immunotherapy was the mainstay of treatment for advanced kidney cancer. The recent development of molecularly targeted agents, and of antiangiogenic agents in particular, has completely changed this scenario, leaving immunotherapy with a minor role in treatment, if any. Recent insights in the mechanisms of resistance to these drugs suggest that the immune system could play a relevant role. In particular, IL-6 appears to cooperate with other growth factors in the recruitment of bone marrow-derived immune cells, ultimately leading to resistance to antiangiogenic agents. Furthermore, it is now clear that monoclonal antibodies actively interact with the immune system and show significant immune-modulating effects per se. Further translation research on this issue is much needed.",
keywords = "IL-6, immunotherapy, kidney cancer, monocolonal antibodies, siltuximab",
author = "Camillo Porta and Paolo Pedrazzoli and Chiara Paglino",
year = "2011",
month = "4",
doi = "10.2217/imt.11.19",
language = "English",
volume = "3",
pages = "487--490",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "4",

}

TY - JOUR

T1 - Is immunotherapy re-entering the kidney cancer arena from the back door? Considerations from the Phase I/II study of siltuximab

AU - Porta, Camillo

AU - Pedrazzoli, Paolo

AU - Paglino, Chiara

PY - 2011/4

Y1 - 2011/4

N2 - Evaluation of: Rossi JF, Negrier S, James ND et al.: A Phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br. J. Cancer 103, 1154-1162 (2010). For years, immunotherapy was the mainstay of treatment for advanced kidney cancer. The recent development of molecularly targeted agents, and of antiangiogenic agents in particular, has completely changed this scenario, leaving immunotherapy with a minor role in treatment, if any. Recent insights in the mechanisms of resistance to these drugs suggest that the immune system could play a relevant role. In particular, IL-6 appears to cooperate with other growth factors in the recruitment of bone marrow-derived immune cells, ultimately leading to resistance to antiangiogenic agents. Furthermore, it is now clear that monoclonal antibodies actively interact with the immune system and show significant immune-modulating effects per se. Further translation research on this issue is much needed.

AB - Evaluation of: Rossi JF, Negrier S, James ND et al.: A Phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br. J. Cancer 103, 1154-1162 (2010). For years, immunotherapy was the mainstay of treatment for advanced kidney cancer. The recent development of molecularly targeted agents, and of antiangiogenic agents in particular, has completely changed this scenario, leaving immunotherapy with a minor role in treatment, if any. Recent insights in the mechanisms of resistance to these drugs suggest that the immune system could play a relevant role. In particular, IL-6 appears to cooperate with other growth factors in the recruitment of bone marrow-derived immune cells, ultimately leading to resistance to antiangiogenic agents. Furthermore, it is now clear that monoclonal antibodies actively interact with the immune system and show significant immune-modulating effects per se. Further translation research on this issue is much needed.

KW - IL-6

KW - immunotherapy

KW - kidney cancer

KW - monocolonal antibodies

KW - siltuximab

UR - http://www.scopus.com/inward/record.url?scp=79953825469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953825469&partnerID=8YFLogxK

U2 - 10.2217/imt.11.19

DO - 10.2217/imt.11.19

M3 - Article

VL - 3

SP - 487

EP - 490

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 4

ER -